Endotoxin Testing for Vaccines: Managing Adjuvant Interference, Method Suitability, and Quality Control

Introduction: Why Endotoxin Testing Matters in Vaccine Manufacturing

Vaccine manufacturing requires rigorous quality control because the final product may contain multiple biological components, formulation ingredients, residual process materials, and excipients. For injectable vaccines, bacterial endotoxin control is an important part of the broader strategy for evaluating product quality and patient safety.

Endotoxins are lipopolysaccharides (LPS) associated with the outer membrane of Gram-negative bacteria. They may enter a manufacturing process through contaminated water, raw materials, equipment, processing components, or other sources of microbial contamination. Because endotoxins can trigger inflammatory and pyrogenic responses, their presence must be controlled according to the applicable product-specific requirements.

However, endotoxin testing for vaccines is not always straightforward. Vaccine formulations may contain proteins, lipids, salts, preservatives, stabilizers, adjuvants, or other substances that affect assay performance. These ingredients can alter endotoxin recovery, influence reaction kinetics, or interfere with optical measurements.

A test result that appears acceptable does not automatically establish that the method can reliably detect endotoxin in a particular vaccine matrix. Laboratories must understand the product being tested, demonstrate method suitability, and establish appropriate controls before relying on the results.

This guide explains the major challenges in vaccine endotoxin testing and provides practical strategies for selecting an assay, evaluating matrix interference, optimizing dilution, interpreting recovery results, and maintaining consistent quality control.

1. Understanding Endotoxin Risk Across Vaccine Manufacturing

Endotoxin control should be considered throughout vaccine manufacturing rather than only at the final testing stage.

Potential sources vary depending on the vaccine platform, manufacturing process, and materials used.

1.1 Raw materials and process water

Water, buffers, salts, and other process materials can introduce endotoxin if their quality and handling are not adequately controlled. Water used for preparation, dilution, cleaning, and other manufacturing operations should meet the specifications appropriate for its intended use.

Raw materials of biological origin may also require careful assessment because their processing history and microbial contamination risks can differ substantially.

A useful starting point is to establish risk-based controls for incoming materials and review the potential contribution of each material to the final product.

For additional background, see FireGene’s guide to endotoxin testing for raw materials and excipients.

1.2 Equipment and manufacturing components

Product-contact equipment, transfer assemblies, filters, tubing, storage containers, and other manufacturing components may introduce contamination if cleaning, handling, or supplier controls are inadequate.

A comprehensive endotoxin control strategy should consider both direct product-contact materials and upstream operations that could influence the quality of the final formulation.

Cleaning validation and routine monitoring can support this strategy by helping manufacturers evaluate whether their procedures adequately control contamination risks.

1.3 Formulation and filling operations

During formulation and filling, the product may contact additional equipment, containers, closures, and process materials. These stages introduce different contamination risks from those encountered during raw-material preparation.

A robust quality system should therefore connect upstream controls, environmental and process monitoring, component qualification, and appropriate finished-product testing.

The goal is not simply to obtain a passing result from one assay. It is to establish a reliable system for preventing contamination, detecting problems, and investigating unexpected findings.

2. Why Vaccine Formulations Can Interfere With Endotoxin Assays

The analytical challenge is often more complex than the presence or absence of endotoxin.

A vaccine matrix can affect the biological reaction, the physical properties of the sample, or the measurement system used to detect the reaction. Different formulations may produce different interference patterns, even when they are tested with the same reagent system.

2.1 Adjuvants and particulate formulations

Some vaccines contain adjuvants designed to enhance the immune response. Depending on the formulation, these may include aluminum-containing particles, emulsions, lipid-based components, or other particulate materials.

These ingredients may affect sample homogeneity, analyte accessibility, pipetting accuracy, or optical measurements. Suspended particles can scatter light, while emulsions and colored components may affect photometric detection.

It is important not to assume that every adjuvant interferes with every endotoxin assay. The impact depends on the specific formulation, assay chemistry, reagent system, and test conditions.

Laboratories should evaluate the actual product matrix instead of relying exclusively on information from a similar formulation.

2.2 Proteins, lipids, and complex biological ingredients

Proteins and lipids can interact with endotoxin in ways that affect its availability to the assay. Some formulations may promote binding or aggregation, while others may alter the recovery of added endotoxin.

These interactions can complicate the interpretation of spike-recovery experiments. A low recovery result may indicate assay inhibition, but it may also reflect matrix-dependent changes in the availability of endotoxin.

For this reason, laboratories should distinguish between demonstrating analytical suitability and establishing the true endotoxin content of a complex biological sample.

2.3 pH, ionic strength, and preservatives

The assay reaction may be sensitive to sample pH and other chemical properties. Preservatives, salts, surfactants, and formulation buffers may influence reagent activity or the behavior of endotoxin in the sample.

Extreme pH or unsuitable ionic conditions can inhibit the reaction or otherwise produce unreliable measurements.

Before testing, laboratories should review the formulation and determine whether sample preparation or dilution is necessary. Any adjustment should be justified and shown not to compromise endotoxin recovery.

2.4 Optical interference in photometric assays

Kinetic chromogenic and turbidimetric methods monitor a measurable signal over time. Their performance may be affected when a sample is highly colored, cloudy, particulate, or otherwise incompatible with the optical measurement system.

In a kinetic chromogenic assay, the reaction produces a colorimetric signal that can be monitored at an appropriate wavelength. A sample that absorbs light strongly or scatters light may complicate the relationship between the observed signal and the endotoxin concentration.

A suitable negative control, appropriate sample preparation, and product-specific method suitability evaluation help laboratories identify these risks.

For more information about assay selection, see FireGene’s guide to gel-clot versus kinetic chromogenic endotoxin testing.

3. Choosing an Appropriate Endotoxin Testing Method

The appropriate method depends on the vaccine formulation, required sensitivity, intended use of the result, available equipment, and applicable regulatory expectations.

No single assay format should be assumed to be suitable for every vaccine.

3.1 Gel-clot endotoxin testing

The gel-clot method detects endotoxin through the formation of a gel under specified test conditions. It can be useful when a qualitative result is sufficient or when a compendial gel-clot approach is appropriate for the product.

Potential advantages include a relatively straightforward endpoint and limited dependence on optical instrumentation.

However, the method still requires appropriate controls and an assessment of product interference. Visual interpretation, sample properties, and the assay's sensitivity can affect practical use.

Learn more about FireGene’s gel-clot endotoxin test kit.

3.2 Kinetic chromogenic endotoxin testing

Kinetic chromogenic testing measures the development of a colorimetric signal over time. Within the validated working range, the reaction time or signal development can be related to endotoxin concentration using an appropriate standard curve.

For vaccine development and process investigations, quantitative data can be useful for comparing samples, evaluating trends, and investigating unexpected results.

The method nevertheless requires appropriate calibration, suitable controls, and demonstrated compatibility with the sample matrix. A quantitative output is not inherently reliable if the matrix interferes with the reaction or measurement.

FireGene’s kinetic chromogenic endotoxin test kit is one option for research and laboratory applications. Its product-specific intended use and limitations should be reviewed before selecting it for a particular workflow.

Important: A research-use-only reagent kit should not be represented as authorized for regulated vaccine release testing. Laboratories must select a method appropriate to their intended use and applicable requirements.

3.3 Recombinant endotoxin detection methods

Recombinant reagent technologies provide additional options for bacterial endotoxin testing. Their suitability depends on the selected technology, product matrix, method performance, and applicable regulatory or compendial requirements.

The FDA’s March 2026 guidance update discusses the broader use of recombinant reagents and emphasizes verifying that the chosen assay is suitable for its intended purpose.

Review the FDA guidance on pyrogen and endotoxin testing when developing a method strategy for a regulated product.

A laboratory should not assume that a method is automatically interchangeable with an established procedure simply because both methods measure endotoxin. Comparability and suitability must be demonstrated for the specific application.

4. Method Suitability Testing: Demonstrating That the Assay Works

Method suitability is one of the most important considerations when testing complex vaccine formulations.

The purpose is to demonstrate that the sample matrix does not prevent the method from detecting endotoxin under the selected test conditions.

A suitable evaluation typically considers the method’s sensitivity, the sample dilution, the behavior of the positive product control, and the applicable acceptance criteria.

4.1 Understand the role of the positive product control

A positive product control (PPC) contains a known amount of endotoxin added to the sample matrix. Its recovery helps evaluate whether the product interferes with the assay under the tested conditions.

If the added endotoxin is recovered within the applicable acceptance range, the result supports the suitability of the method under those specific conditions.

If recovery is outside the acceptable range, the laboratory should investigate potential inhibition, enhancement, sample-preparation problems, or other causes before relying on the test result.

A PPC does not prove that the sample is endotoxin-free. It provides evidence about the method’s performance in the presence of the tested matrix.

4.2 Select an appropriate endotoxin spike

The spike concentration should be appropriate for the method and the applicable suitability procedure. It should allow the laboratory to evaluate the assay without creating an artificially easy test condition.

Laboratories should use qualified endotoxin standards and follow the reagent manufacturer's instructions and applicable compendial requirements.

FireGene’s control standard endotoxin products may support appropriate laboratory workflows when selected and used according to their specifications.

4.3 Evaluate the sample matrix under actual test conditions

Suitability should be evaluated using the relevant formulation, sample preparation, dilution, and assay conditions.

Testing a buffer alone may not establish suitability for the finished vaccine, because the final formulation may contain additional ingredients that affect recovery or measurement.

Where formulations differ materially, laboratories should determine whether separate suitability evaluations are needed rather than assuming that one result applies to every product.

For a more detailed discussion of recovery experiments, see FireGene’s guide to endotoxin recovery studies.

5. Optimizing Sample Dilution Without Losing Sensitivity

Dilution is a common strategy for reducing matrix interference. However, dilution also lowers the endotoxin concentration presented to the assay.

The challenge is to reduce interference while retaining sufficient analytical sensitivity to evaluate the sample against the applicable limit.

5.1 Start with the required sensitivity

Before selecting a dilution, establish the endotoxin limit or other applicable acceptance criterion for the product. The appropriate limit depends on the product and its regulatory context; a universal limit should not be assumed for every vaccine.

The method’s sensitivity and the proposed dilution must allow the laboratory to evaluate the sample at the required level.

A dilution that eliminates interference but makes the assay insufficiently sensitive is not a successful solution.

5.2 Evaluate a dilution series when justified

When interference is suspected, a planned dilution study can help identify conditions that provide acceptable PPC recovery while maintaining adequate sensitivity.

The laboratory should document the tested dilutions, sample preparation, controls, results, and rationale for selecting the final conditions.

A dilution series should not be used simply to obtain a passing result. The selected dilution must be scientifically justified and compatible with the intended analytical decision.

5.3 Understand the maximum valid dilution

The maximum valid dilution (MVD) is a key consideration when establishing how far a sample may be diluted without compromising the ability to detect endotoxin at the applicable limit.

The calculation depends on factors such as the endotoxin limit and the assay sensitivity. Its application must also account for the specific product and relevant test requirements.

A dilution exceeding the justified MVD may prevent the method from reliably detecting endotoxin at the required level.

For further guidance, read FireGene’s practical guide to endotoxin testing sensitivity, LOD, LOQ, and MVD.

6. Understanding Low Endotoxin Recovery in Complex Formulations

Low endotoxin recovery (LER) is particularly relevant when endotoxin interacts with components of a formulation or sample matrix.

Under certain conditions, endotoxin added to a sample may become less recoverable by the selected assay over time. This can occur even when the analytical method initially demonstrates acceptable recovery.

LER is not simply another name for a failed PPC. It describes a recovery problem that may depend on the formulation and the time elapsed between sample preparation and testing.

6.1 Why recovery can change over time

Interactions among endotoxin, proteins, lipids, surfactants, and other formulation components may influence the amount of endotoxin available for detection.

As a result, a sample tested immediately after preparation may behave differently from the same sample tested after a prolonged hold.

This is one reason why method suitability, sample handling, and sample hold-time evaluations should be considered together when developing a robust testing strategy.

6.2 Investigate recovery patterns systematically

When low recovery is observed, laboratories should review:

• The formulation composition and potential endotoxin-binding components.

• Sample preparation and dilution conditions.

• The timing of endotoxin addition and sample testing.

• The suitability and performance of controls.

• Storage conditions and the established sample hold time.

• Whether the observed pattern is reproducible.

Changes to sample preparation should be supported by data. Laboratories should not assume that increasing dilution or changing the test method will automatically resolve an LER issue.

For additional technical background, see FireGene’s guide to low endotoxin recovery.

7. Establishing a Practical Vaccine Endotoxin QC Workflow

A reliable workflow combines risk assessment, method selection, suitability testing, controlled sample handling, and documented review.

The following sequence provides a practical framework for laboratory planning.

Step 1: Define the testing objective

Determine whether the test supports process development, in-process monitoring, raw-material evaluation, investigation, or finished-product quality control.

The objective influences the required sensitivity, method, controls, and acceptance criteria.

Step 2: Review the formulation and contamination risks

Identify formulation ingredients and manufacturing materials that may affect endotoxin contamination risk or assay performance.

Pay particular attention to complex matrices, particulate components, preservatives, and ingredients that may influence endotoxin recovery.

Step 3: Select the analytical method

Choose a method based on the product matrix, required analytical performance, available instrumentation, and applicable requirements.

Document the rationale for selecting the method rather than relying only on convenience or instrument availability.

Step 4: Demonstrate method suitability

Evaluate interference using appropriate controls and a justified spike-recovery procedure.

If the results do not meet the applicable criteria, investigate the cause before using the method to support product decisions.

Step 5: Establish sample preparation and handling conditions

Define the required dilution, mixing procedure, storage conditions, and time between preparation and testing.

Where sample stability or recovery may change over time, generate supporting data rather than assuming that the sample remains unchanged.

Step 6: Apply routine quality controls

Use the controls required by the selected method and applicable procedure. Review the standard curve where relevant, negative controls, PPC recovery, and other method-specific performance indicators.

A sample result should not be interpreted in isolation when the associated assay controls indicate that the run may be invalid.

Step 7: Document results and investigate deviations

Maintain records of sample identity, preparation, reagent lot information, calculations, controls, and test conditions.

When results are unexpected, investigate the analytical method and manufacturing process systematically. Avoid repeating tests without a documented rationale or changing conditions solely to obtain a passing result.

Step 8: Review trends and update risk controls

Trend endotoxin results across relevant raw materials, process stages, and finished-product batches when appropriate.

A gradual shift in results may warrant investigation before an individual result exceeds its acceptance criterion.

FireGene’s guide to endotoxin testing trend analysis discusses how laboratories can use data trends to support early problem detection.

8. Common Mistakes in Vaccine Endotoxin Testing

Even laboratories with established procedures can encounter problems when testing complex biological products.

Mistake 1: Assuming one method works for every formulation

Two vaccines may differ in pH, lipid content, adjuvant composition, or other matrix characteristics. Method suitability should be assessed for the relevant product and conditions.

Mistake 2: Treating acceptable recovery as proof of product safety

PPC recovery supports the suitability of the method under the tested conditions. It does not independently establish that the sample meets its endotoxin specification or is free of other pyrogens.

Mistake 3: Increasing dilution without checking sensitivity

Dilution may reduce interference but also reduce the amount of endotoxin available for detection. The final dilution must remain compatible with the required sensitivity and applicable MVD.

Mistake 4: Ignoring sample hold time

If endotoxin recovery changes during storage or holding, the timing of testing may influence the observed result. Hold-time conditions should be evaluated when relevant to the formulation.

Mistake 5: Overlooking reagent and water quality

Contaminated water, unsuitable consumables, or improperly handled reagents can compromise the reliability of an assay.

Use appropriate endotoxin testing materials, qualified reagents, and suitable laboratory practices. FireGene’s endotoxin assay water and pyrogen-free vials are examples of materials that may be considered for compatible laboratory workflows according to their specifications.

Mistake 6: Confusing endotoxin testing with comprehensive pyrogen testing

Bacterial endotoxin assays target endotoxins from Gram-negative bacteria. They do not automatically detect every substance capable of causing a pyrogenic response.

The broader strategy for evaluating pyrogen risk should be determined according to the product, applicable requirements, and relevant scientific evidence.

9. Regulatory Considerations for Vaccine Endotoxin Testing

Regulatory expectations depend on the vaccine, jurisdiction, product authorization, and applicable compendial requirements.

For US-regulated products, laboratories should review relevant FDA guidance and applicable USP chapters, including USP General Chapter <85>, Bacterial Endotoxins Test, where relevant.

The FDA’s March 2026 revision of Pyrogen and Endotoxins Testing: Questions and Answers discusses the agency’s current thinking on endotoxin and pyrogen testing, including assay methods and recombinant reagent technologies. It also emphasizes the need to verify that a selected method is suitable for its intended purpose.

For laboratories considering recombinant reagent approaches, the availability of a method does not eliminate the need for product-specific suitability assessment and appropriate documentation.

Regulatory requirements should not be inferred from a general blog post. The applicable product specification, approved manufacturing controls, compendial requirements, and current agency guidance should be reviewed by the responsible quality and regulatory teams.

Reference: FDA — Pyrogen and Endotoxins Testing: Questions and Answers.

10. Supporting Reliable Endotoxin Testing With Appropriate Reagents

Reagent selection is one part of a complete analytical strategy. Laboratories should also consider the intended application, reagent sensitivity, compatibility with the chosen method, control materials, water quality, consumables, and handling procedures.

For laboratories evaluating assay options, FireGene provides a range of endotoxin testing reagents and related materials for research and laboratory applications.

Relevant resources include:

• Kinetic Chromogenic Endotoxin Test Kit

• Gel-Clot Endotoxin Test Kit

• Control Standard Endotoxin

• Endotoxin Assay Water

• Pyrogen-Free Vials

• FireGene Endotoxin Assay Reagents and Kits

The appropriate product should be selected according to its specifications and intended use. For regulated vaccine quality control, laboratories must independently establish that the chosen method and reagents meet the applicable requirements.

Conclusion: Build a Product-Specific Strategy for Vaccine Endotoxin Testing

Vaccine endotoxin testing requires more than choosing an assay and obtaining a numerical result. Complex formulations, adjuvants, sample preparation, endotoxin recovery, and storage conditions can all influence analytical performance.

A reliable approach begins with understanding contamination risks and the product matrix. It then combines appropriate method selection, demonstrated suitability, justified dilution, controlled sample handling, and systematic review of assay controls.

By integrating these elements into a documented quality control strategy, laboratories can improve the reliability and interpretability of endotoxin results while supporting consistent manufacturing decisions.

For vaccine developers and QC teams, the central principle is straightforward: a reliable endotoxin result depends on both a suitable analytical method and evidence that the method performs appropriately in the actual sample matrix.

Explore FireGene’s endotoxin assay reagents and kits for research and laboratory applications.

Disclaimer: This article is for educational purposes only and does not replace applicable pharmacopoeial requirements, approved product specifications, validated procedures, or regulatory guidance. Product-specific method suitability and acceptance criteria must be established by the responsible laboratory.